Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

High risk MDS in the wke of anti-BCMA CART therapy in refractory multiple myeloma.

View Full Paper
Ask AI
Bookmark
Share

Authors

DGDavid Gorlin

Discussion

Loading...

Member takes

Overview

Case report reveals development of high-risk myeloid neoplasm post-anti-BCMA CAR T-cell therapy in refractory multiple myeloma, suggesting potential long-term effects of treatment.

Key Points

  • Severe, persistent cytopenias developed after anti-BCMA CAR T-cell therapy, leading to a diagnosis of high-risk therapy-related myeloid neoplasm.
  • Analysis identified TP53 missense mutation and complex karyotype with abnormalities involving chromosomes 5 and 7.
  • Observational analysis of patient outcomes highlights the complexities of treatment-related complications in multiple myeloma therapies.
  • The findings may emphasize the need for continuous monitoring and further investigation into potential long-term effects of CAR T-cell therapies.

Cite This Study

David Gorlin (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc1fhttps://doi.org/10.1182/blood-2025-7609
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1BCMA-CART therapy in 29 cases of relapsed or refractory multiple myeloma:a retrospective study2025
  2. 2Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy2025 · 20 citations
  3. 3Anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma with extramedullary disease: Comparative outcomes and evolving strategies2025
  4. 4Long-term follow-up of patients with relapsed/refractory multiple myeloma after BCMA CAR-T-cell therapy2025 · 3 citations
  5. 5Impact of prior BCMA-targeted therapy on CAR-T expansion and host T-cell phenotypes in patients with Relapsed/Refractory multiple myeloma receiving BCMA CAR-T therapy2025